<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919723</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0077</org_study_id>
    <nct_id>NCT01919723</nct_id>
  </id_info>
  <brief_title>Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion</brief_title>
  <official_title>Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to measure platelet response to ticagrelor and eptifibatide
      bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion
      administrated after cardiac catheterization in patients undergoing non-emergent percutaneous
      coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 60 patients with Acute Coronary Syndrome who are undergoing non-emergent
      percutaneous coronary intervention (PCI) will be randomized to ticagrelor loading dose and
      eptifibatide bolus-only versus ticagrelor loading dose and eptifibatide bolus plus 2 hour
      infusion administrated after cardiac catheterization, but before PCI. Platelet function
      testing will be performed at baseline and follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in percent inhibition of platelet activity</measure>
    <time_frame>Comparing baseline with follow-up (6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in percent inhibition of platelet activity (%IPA) at 6 hours measured in the blood by an aggregomter among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations between platelet activity inhibition</measure>
    <time_frame>Comparing baseline and follow-up (6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlations between the percent inhibition of platelet activity (% IPA) in the blood measured by an aggregomter after exposure of blood to agonists such as adenosine diphosphate versus thrombin receptor agonist peptide.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of bleeding complications</measure>
    <time_frame>Comparing baseline and follow-up (18 hours)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparison of bleeding complications in patients randomized to ticagrelor and 2 boluses of eptifibatide with ticagrelor and 2 boluses plus 2-h infusion of eptifibatide.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>ticagrelor loading dose</description>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <other_name>brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>i.v. infusion</description>
    <arm_group_label>Ticagrelor and Eptifibatide bolus</arm_group_label>
    <arm_group_label>Ticagrelor &amp; Eptifibatide bolus+infusion</arm_group_label>
    <other_name>integrilin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For inclusion in the study subjects should fulfill the following criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Males and females aged 19 years and older

          -  Congruent to the PLATO trial, at least two of the following three criteria have to be
             met:

          -  ST-segment changes on electrocardiography, indicating ischemia;

          -  a positive test of a biomarker, indicating myocardial necrosis; or one of several
             risk factors;

          -  age &gt;60 years

          -  previous myocardial infarction or coronary-artery bypass grafting [CABG];

          -  coronary artery disease with stenosis of ≥50% in at least two vessels;

          -  previous ischemic stroke, transient ischemic attack, carotid stenosis of at least
             50%, or cerebral revascularization;

          -  diabetes mellitus;

          -  peripheral arterial disease;

          -  or chronic renal dysfunction, defined as a creatinine clearance of &lt;60 ml per minute
             per 1.73 m2 of body surface area).

          -  patients with symptoms of unstable angina lasting ≥10 min and either an  elevated
             troponin I level or newly developed ST-segment depression of 1 mm or transient
             ST-segment elevation of 1 mm will also be included.

        Exclusion Criteria:

        Subjects should not enter the study if any of the following exclusion criteria are
        fulfilled:

          -  Patients with active pathological bleeding or a history of intracranial bleeding;

          -  patients with planned to urgent coronary artery bypass graft surgery;

          -  severe hepatic impairment;

          -  concomitant therapy with a strong cytochrome P-450 3A inhibitors;

          -  surgery&lt;4 weeks;

          -  the use of any thienopyridine (within the previous two weeks);

          -  upstream use of GP IIb/IIIa inhibitors;

          -  bleeding diathesis or major bleeding episode within 2 weeks;

          -  a need for oral anticoagulation therapy;

          -  thrombocytopenia;

          -  presence of thrombus in the coronary artery; incessant chest pain or hemodynamic
             instability;

          -  and patients with GFR&lt;30 mL/min or on hemodialysis.

          -  maintenance dose of aspirin above 100mg

          -  history of allergies to Ticagrelor

          -  patients at increased risk of bradycardic events (e.g., patients who have sick sinus
             syndrome, 2nd or 3rd degree AV block, or bradycardic related syncope and not
             protected with a pacemaker

          -  women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massoud Leesar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Harshberger, RN</last_name>
    <phone>205-975-9426</phone>
    <email>jharsh@uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massoud Leesar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ginger Conway, MSN, RN</last_name>
      <phone>513-558-3476</phone>
      <email>conwaygg@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed A Effat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Eptifibatide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eptifibatide</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
